iShares U.S. Healthcare ETF News - September 26, 2026

Novo Nordisk Signs $1.33B Nanexa Deal for Long-Acting Obesity and Diabetes Drugs

Novo Nordisk has signed a licensing agreement with Swedish drug delivery firm Nanexa worth up to €1.165 billion ($1.33 billion). The deal gives Novo Nordisk...